A-Alpha Bio is a biotechnology company specializing in synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions. Founded in 2017 as a spinoff from the University of Washington's Institute for Protein Design and Center for Synthetic Biology, the company is based in Seattle, Washington. A-Alpha Bio's pioneering tools, AlphaSeq and AlphaBind, facilitate high-throughput and quantitative assessments of protein interactions, which accelerate the discovery and development of novel therapeutics. As of 2024, the company has raised approximately $51 million in funding to further expand its innovative platforms and therapeutic programs.
| Attribute | Information |
|---|---|
| Founding Date | 2017 |
| Headquarters | Seattle, Washington, United States |
| Founders | University of Washington's Institute for Protein Design |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | Perceptive Advisors Xontogeny Ventures, Madrona |
| Industry | Biotechnology |
| Number of Employees | Not publicly disclosed |
A-Alpha Bio emerged from the University of Washington's Institute for Protein Design in 2017. The founders, leveraging their academic expertise, aimed to address limitations in protein interaction data that affect drug discovery processes. Positioned at the intersection of synthetic biology and machine learning, the company's early strategy involved developing technologies that could handle high-throughput assessment of protein interactions, which was anticipated to revolutionize the field of drug discovery. The foundational technology, AlphaSeq, was introduced to enable multiplexed characterization of these interactions, setting the stage for its future successes in partnerships and funding rounds.
A-Alpha Bio's business model revolves around utilizing its proprietary AlphaSeq and AlphaBind platforms to expedite drug discovery. These platforms allow for rapid evaluation and improvement of protein interactions, crucial for identifying potential therapeutic targets. Significant Achievements:
A-Alpha Bio continues to disrupt the biotechnology industry with its state-of-the-art platforms for studying protein-protein interactions. Their operations focus on both in-house therapeutic programs and collaborations with pharmaceutical giants to discover novel treatments. By combining synthetic biology with machine learning, A-Alpha Bio holds a competitive edge in rapidly generating and analyzing complex data sets. This capability is especially advantageous in biothreat threat assessment and therapeutic development, ensuring their strong positioning for future growth and influence.
A-Alpha Bio stands out as a pivotal player in the biotechnology sector by addressing critical bottlenecks in drug development. Its innovative use of synthetic biology and machine learning through the AlphaSeq and AlphaBind platforms places it at the forefront of protein interaction research, facilitating discoveries that could significantly impact healthcare. The company's recent advancements, robust collaborations, and strategic investments suggest a promising trajectory in addressing global therapeutic needs, reinforcing its role as an industry trailblazer.